FDA Provides Fast Track Designation to Nipocalimab for Systemic Lupus Erythematosus

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

WEDNESDAY, March 11, 2026 -- Nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE).

Fast Track designation is designed to expedite the development and review of drugs that demonstrate the potential to treat serious conditions with unmet treatment needs. Nipocalimab is an immunoselective investigational therapy that lowers immunoglobulin G, one of the root causes of autoantibody-driven diseases, while preserving critical immune functions.

The Fast Track designation was supported by results from the 52-week phase 2 JASMINE study, in which 228 adult participants with active SLE were randomly assigned to nipocalimab of varying doses or placebo. Nipocalimab demonstrated reduced lupus disease activity in patients, as well as the potential for steroid sparing. A phase 3 study is ongoing.

"Nipocalimab earning its fifth FDA Fast Track designation, now in SLE, reflects the importance of accelerating the delivery of an immunoselective therapy that could fill an unmet need in this serious condition," Leonard L. Dragone, M.D., Ph.D., from Johnson & Johnson, said in a statement. "This is an important step in our efforts to help address the ongoing burden faced by people living with this debilitating disease."

Fast Track designation of nipocalimab was granted to Johnson & Johnson.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-12 08:45

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords